The estimated Net Worth of Shehnaaz Suliman is at least $5.47 Milion dollars as of 10 December 2021. Shehnaaz Suliman owns over 150,000 units of 10x Genomics stock worth over $3,924,916 and over the last 7 years he sold TXG stock worth over $0. In addition, he makes $1,545,950 as Independent Director at 10x Genomics.
Sign up
Shehnaaz Suliman TXG stock SEC Form 4 insiders trading
Shehnaaz has made over 2 trades of the 10x Genomics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 150,000 units of TXG stock worth $2,584,500 on 10 December 2021.
The largest trade he's ever made was exercising 150,000 units of 10x Genomics stock on 10 December 2021 worth over $2,584,500. On average, Shehnaaz trades about 13,636 units every 0 days since 2017. As of 10 December 2021 he still owns at least 177,598 units of 10x Genomics stock.
You can see the complete history of Shehnaaz Suliman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Shehnaaz Suliman biography
Dr. Shehnaaz Suliman serves as Independent Director of the Company. She has served on our board or directors since August 2019. In addition, Dr. Suliman has served on the board of directors for Ultragenyx Pharmaceutical Inc. since January 2019. She has served as President and Chief Executive Officer of Alector, Inc. since December 2019. Dr. Suliman served as Senior Vice President, Corporate Development and Strategy of Theravance Biopharma, Inc, from July 2017 to March 2019. Prior to her position at Theravance, Dr. Suliman worked for Roche and Genentech, Inc., as Group Leader and Project Team Leader in the R&D Portfolio Management and Operations Group at Genentech from September 2010 to May 2015 and then as Vice President and Global Therapeutic Area Head, Roche Partnering from June 2015 to July 2017. Prior to Genentech, Dr. Suliman held various management roles of increasing responsibility at Gilead Sciences, Inc., between January 2005 and September 2010. Prior to Gilead, Dr. Suliman was an investment banker with Lehman Brothers and Petkevich & Partners. She has previously served as a member of the board of directors of Parvus Therapeutics, Inc., a private biopharmaceutical company from October 2017 to July 2019. Dr. Suliman received her M.D. (MB, ChB) at the University of Cape Town Medical School, South Africa, and holds an M.B.A, with distinction, and M.Phil. in Development Studies degrees from Oxford University, where she was a Rhodes Scholar.
What is the salary of Shehnaaz Suliman?
As the Independent Director of 10x Genomics, the total compensation of Shehnaaz Suliman at 10x Genomics is $1,545,950. There are 3 executives at 10x Genomics getting paid more, with Serge Saxonov having the highest compensation of $2,362,960.
How old is Shehnaaz Suliman?
Shehnaaz Suliman is 48, he's been the Independent Director of 10x Genomics since 2019. There are 8 older and 8 younger executives at 10x Genomics. The oldest executive at 10x Genomics, Inc. is John Stuelpnagel, 62, who is the Independent Chairman of the Board.
What's Shehnaaz Suliman's mailing address?
Shehnaaz's mailing address filed with the SEC is C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO, CA, 94949.
Insiders trading at 10x Genomics
Over the last 5 years, insiders at 10x Genomics have traded over $629,686,183 worth of 10x Genomics stock and bought 487,816 units worth $19,025,295 . The most active insiders traders include Bryan E Roberts, Capital Management I, Llc F... a Benjamin J. Hindson. On average, 10x Genomics executives and independent directors trade stock every 8 days with the average trade being worth of $1,002,346. The most recent stock trade was executed by Serge Saxonov on 22 August 2024, trading 6,749 units of TXG stock currently worth $152,055.
What does 10x Genomics do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
What does 10x Genomics's logo look like?
Complete history of Shehnaaz Suliman stock trades at Theravance Biopharma Inc, Ultragenyx Pharmaceutical, 10x Genomics a Alector
10x Genomics executives and stock owners
10x Genomics executives and other stock owners filed with the SEC include:
-
Serge Saxonov,
Chief Executive Officer, Co-Founder, Director -
Benjamin Hindson,
President, Co-Founder, Chief Scientific Officer, Director -
Sridhar Kosaraju,
Independent Director -
Shehnaaz Suliman,
Independent Director -
Eric Whitaker,
General Counsel -
Bryan Roberts,
Independent Director -
Dr. Serge Saxonov Ph.D.,
Co-Founder, CEO & Director -
Justin McAnear,
Chief Financial Officer -
Dr. Benjamin J. Hindson Ph.D.,
Co-Founder, Pres, Chief Scientific Officer & Director -
Bradford J. Crutchfield,
Chief Commercial Officer -
Ruth De Backer,
Chief Bus. Officer -
Justin J. McAnear,
Chief Financial Officer -
John Stuelpnagel,
Independent Chairman of the Board -
Mathai Mammen,
Independent Director -
Kimberly Popovits,
Independent Director -
Bradford Crutchfield,
Chief Commercial Officer -
Jean Philibert,
Chief People Officer -
Sam Ropp,
Sr. VP of Global Sales -
Jonathan Schimmel,
VP of Global Support & Sales Operations -
Eric S. Whitaker,
Gen. Counsel -
Cassie Corneau,
Mang. of Investor Relations and Strategic Fin. -
Paul W. Wyatt,
Sr. VP of Operations -
Capital Management, Llc Pal...,
-
Associates Vi, L.P.Venrock ...,
-
Vision Fund (Aiv M2) L.P.Sb...,
-
Capital Management I, Llc F...,
-
Sarah A. Teichmann,
-
James Wilbur,
Chief Commercial Officer -
Alan Mateo,